Bailard’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12.4M | Buy |
13,534
+762
| +6% | +$773K | 0.29% | 77 |
|
|
2025
Q4 | $13.7M | Sell |
12,772
-634
| -5% | -$606K | 0.3% | 70 |
|
|
2025
Q3 | $10.2M | Buy |
13,406
+416
| +3% | +$310K | 0.22% | 96 |
|
|
2025
Q2 | $10.1M | Sell |
12,990
-77
| -0.6% | -$59.8K | 0.24% | 95 |
|
|
2025
Q1 | $10.8M | Buy |
13,067
+22
| +0.2% | +$18.3K | 0.28% | 84 |
|
|
2024
Q4 | $10.1M | Buy |
13,045
+1,852
| +17% | +$1.53M | 0.26% | 88 |
|
|
2024
Q3 | $9.92M | Sell |
11,193
-1,904
| -15% | -$1.71M | 0.26% | 89 |
|
|
2024
Q2 | $11.9M | Buy |
13,097
+546
| +4% | +$437K | 0.33% | 70 |
|
|
2024
Q1 | $9.76M | Sell |
12,551
-436
| -3% | -$310K | 0.27% | 86 |
|
|
2023
Q4 | $7.57M | Buy |
12,987
+576
| +5% | +$336K | 0.22% | 97 |
|
|
2023
Q3 | $6.67M | Sell |
12,411
-1,731
| -12% | -$892K | 0.22% | 98 |
|
|
2023
Q2 | $6.63M | Buy |
14,142
+3,801
| +37% | +$1.59M | 0.23% | 94 |
|
|
2023
Q1 | $3.55M | Sell |
10,341
-134
| -1% | -$45.2K | 0.13% | 140 |
|
|
2022
Q4 | $3.83M | Sell |
10,475
-105
| -1% | -$37.2K | 0.15% | 127 |
|
|
2022
Q3 | $3.42M | Buy |
10,580
+627
| +6% | +$199K | 0.14% | 134 |
|
|
2022
Q2 | $3.23M | Buy |
9,953
+2,315
| +30% | +$695K | 0.13% | 147 |
|
|
2022
Q1 | $2.19M | Sell |
7,638
-945
| -11% | -$243K | 0.07% | 198 |
|
|
2021
Q4 | $2.37M | Sell |
8,583
-15
| -0.2% | -$3.8K | 0.08% | 191 |
|
|
2021
Q3 | $1.99M | Buy |
8,598
+404
| +5% | +$99.7K | 0.07% | 198 |
|
|
2021
Q2 | $1.88M | Buy |
8,194
+181
| +2% | +$36.4K | 0.07% | 206 |
|
|
2021
Q1 | $1.5M | Buy |
8,013
+2,103
| +36% | +$411K | 0.06% | 226 |
|
|
2020
Q4 | $998K | Sell |
5,910
-680
| -10% | -$102K | 0.05% | 215 |
|
|
2020
Q3 | $975K | Buy |
6,590
+288
| +5% | +$44.6K | 0.05% | 202 |
|
|
2020
Q2 | $1.03M | Buy |
6,302
+3,357
| +114% | +$515K | 0.06% | 191 |
|
|
2020
Q1 | $409K | Sell |
2,945
-20
| -0.7% | -$2.75K | 0.03% | 257 |
|
|
2019
Q4 | $390K | Sell |
2,965
-42
| -1% | -$4.87K | 0.02% | 364 |
|
|
2019
Q3 | $336K | Sell |
3,007
-300
| -9% | -$33.4K | 0.02% | 374 |
|
|
2019
Q2 | $366K | Buy |
3,307
+508
| +18% | +$59.8K | 0.02% | 369 |
|
|
2019
Q1 | $363K | Buy |
2,799
+127
| +5% | +$15.4K | 0.02% | 375 |
|
|
2018
Q4 | $309K | Buy |
2,672
+92
| +4% | +$10.3K | 0.02% | 412 |
|
|
2018
Q3 | $277K | Buy |
+2,580
| New | +$258K | 0.02% | 475 |
|
|
2018
Q1 | – | Sell |
-2,732
| Closed | -$231K | – | 494 |
|
|
2017
Q4 | $231K | Buy |
2,732
+310
| +13% | +$26.4K | 0.01% | 406 |
|
|
2017
Q3 | $207K | Buy |
+2,422
| New | +$199K | 0.02% | 287 |
|
|
2017
Q2 | – | Sell |
-2,422
| Closed | -$204K | – | 290 |
|
|
2017
Q1 | $204K | Buy |
+2,422
| New | +$194K | 0.02% | 285 |
|
Other funds holding LLY
VCM
VPM
Bailard's LLY Position: Q1 2026 in Review
Bailard increased its Eli Lilly (LLY) stake by 6% in Q1 2026, buying an estimated $773K and bringing the position to 13,534 shares worth $12.4M. The position accounts for 0.29% of the portfolio, ranked #77.
Bailard first reported a position in LLY in Q1 2017 and has held it in 34 quarters since. The position peaked at $13.7M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Bailard held 13,534 shares of Eli Lilly worth $12.4M as of Q1 2026.
- Bailard bought 762 Eli Lilly shares in Q1 2026, an estimated $773K.
- Eli Lilly made up 0.29% of Bailard's portfolio in Q1 2026, its #77 holding.
- Bailard first reported a position in Eli Lilly in Q1 2017 and has held it in 34 quarters since.
- Bailard's Eli Lilly position peaked at $13.7M in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Bailard's 13F filing for Q1 2026, filed 11 May 2026.